Search results for "protocols"

showing 10 items of 782 documents

Automated Synthesis of Application-layer Connectors from Automata-based Specifications

2019

Abstract Ubiquitous and Pervasive Computing, and the Internet of Things, promote dynamic interaction among heterogeneous systems. To achieve this vision, interoperability among heterogeneous systems represents a key enabler, and mediators are often built to solve protocol mismatches. Many approaches propose the synthesis of mediators. Unfortunately, a rigorous characterization of the concept of interoperability is still lacking, hence making hard to assess their applicability and soundness. In this paper, we provide a framework for the synthesis of mediators that allows us to: (i) characterize the conditions for the mediator existence and correctness; and (ii) establish the applicability bo…

CorrectnessUbiquitous computingGeneral Computer ScienceComputer Networks and CommunicationsComputer scienceDistributed computingInteroperability0102 computer and information sciences02 engineering and technology01 natural sciencesHeterogeneous ApplicationsTheoretical Computer Science020204 information systems0202 electrical engineering electronic engineering information engineeringProtocol MismatchesCommunication & CoordinationProtocol (object-oriented programming)Automated Mediator SynthesisSoundnessApplied MathematicsAutomated Mediator Synthesis Interoperability Protocols Heterogeneous Applications Communication & Coordination Protocol MismatchesInteroperabilityApplication layerAutomatonComputational Theory and Mathematics010201 computation theory & mathematicsKey (cryptography)Protocols
researchProduct

Multiple modes of cell death in neuroendocrine tumors induced by artesunate.

2020

Abstract Background The paucity of effective treatment in neuroendocrine tumors (NETs) encouraged us to investigate the therapeutic value of artesunate (ART) promised by its inhibitory effect against various tumors and broad safety profile. Methods We evaluated the impact of ART on three NET cell lines, BON-1, QGP-1 and NCI-H727 on cellular and molecular levels. Results Our results showed that ART induced endoplasmic reticulum (ER) stress through phosphorylation of eIF2α, which further gave rise to autophagy in all three NET cell lines. Specifically, apoptosis and ferroptosis were also observed in BON-1 cells, which made BON-1 cell line more vulnerable upon ART treatment. The different sens…

Cyclin-Dependent Kinase Inhibitor p21NiacinamideProgrammed cell deathPharmaceutical ScienceArtesunateAntineoplastic AgentsApoptosisNeuroendocrine tumorsBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationCell Line TumorDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineAutophagyFerroptosisHumans030304 developmental biologyPharmacology0303 health sciencesEndoplasmic reticulumPhenylurea CompoundsAutophagymedicine.diseaseEndoplasmic Reticulum StressNeuroendocrine TumorsComplementary and alternative medicinechemistryCell cultureApoptosisArtesunate030220 oncology & carcinogenesisCancer researchMolecular MedicinePhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Daratumumab for the Treatment of Multiple Myeloma

2018

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38Frontiers in Immunology
researchProduct

Antitumor Effects of a Combined 5-Aza-2′Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice

2009

Abstract Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here, we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza-2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prev…

DNA (Cytosine-5-)-Methyltransferase 1Patched ReceptorsPatchedCancer Researchmedicine.drug_classGene ExpressionDecitabineReceptors Cell SurfaceBiologyDecitabineHistone DeacetylasesHistonesMice03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineAnimalsDNA (Cytosine-5-)-MethyltransferasesGene SilencingMuscle SkeletalRhabdomyosarcoma030304 developmental biologyMedulloblastomaMice Inbred BALB C0303 health sciencesValproic AcidHistone deacetylase inhibitorCancerAcetylationDNA Methylationmedicine.disease3. Good healthHistone Deacetylase InhibitorsMice Inbred C57BLPatched-1 Receptorstomatognathic diseasesOncology030220 oncology & carcinogenesisAzacitidineCancer researchDNMT1Epigenetic therapyMedulloblastomamedicine.drugCancer Research
researchProduct

Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

2021

Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials.Area covered: This review aims to give an overview of patents published since 2010 by analyzing the patent space and structure features of scaffolds used in those patents. It also discusses the recent clinical developments and provides perspectives on future challenges and directions in this field.Expert opinion: As a key component of the DNA damage response (DDR) pathway, DNA-PK appears to be a viable drug target for anticancer therapy. The clinical investi…

DNA damageCancer therapyDNA-Activated Protein Kinase01 natural sciencesPatents as Topic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DevelopmentNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug DiscoveryCombination strategyAnimalsHumansMedicineProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryGeneral MedicineSmall molecule0104 chemical sciences010404 medicinal & biomolecular chemistrychemistryAnticancer treatment030220 oncology & carcinogenesisPARP inhibitorCancer researchbusinessDNADNA DamageExpert Opinion on Therapeutic Patents
researchProduct

Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania

2020

Background and objectives: Breast cancer is among the most common cancer types encountered during pregnancy. Here, we aimed to describe the characteristics, management, and outcomes of women with pregnancy-associated breast cancer at a tertiary-level hospital in Romania. Material and Methods: We retrospectively and prospectively collected demographic, oncological, and obstetrical data for women diagnosed with cancer during pregnancy, and who elected to continue their pregnancy, between June 2012 and June 2020. Complete data were obtained regarding family and personal medical history and risks factors, cancer diagnosis and staging, clinical and pathological features (including histology and …

Data AnalysisPediatricsmedicine.medical_specialtymedicine.medical_treatmentbreast cancer; pregnancy-associated breast cancer; RomaniaBreast NeoplasmsArticleBreast cancerbreast cancerPregnancyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildbirthMedical historyStage (cooking)ChildNeoplasm StagingRetrospective Studieslcsh:R5-920PregnancyChemotherapybusiness.industrypregnancy-associated breast cancerRomaniaCancerGeneral Medicinemedicine.diseaseHospitalsNeoadjuvant TherapyRadiation therapyFemaleNeoplasm Recurrence Locallcsh:Medicine (General)businessMedicina
researchProduct

Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

2006

The Cancer Imaging Program of the National Cancer Institute convened a workshop to assess the current status of hypoxia imaging, to assess what is known about the biology of hypoxia as it relates to cancer and cancer therapy, and to define clinical scenarios in which in vivo hypoxia imaging could prove valuable.Hypoxia, or low oxygenation, has emerged as an important factor in tumor biology and response to cancer treatment. It has been correlated with angiogenesis, tumor aggressiveness, local recurrence, and metastasis, and it appears to be a prognostic factor for several cancers, including those of the cervix, head and neck, prostate, pancreas, and brain. The relationship between tumor oxy…

Diagnostic ImagingOncologymedicine.medical_specialtyCancer therapyBiologyAntigens NeoplasmNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingMedical physicsCarbonic Anhydrase IXHypoxiaCarbonic AnhydrasesCancer Imaging ProgramRadiological and Ultrasound TechnologyTumor biologyReproducibility of ResultsHypoxia (medical)PrognosisUnited StatesCancer treatmentIsoenzymesOxygenRadiographyNational Institutes of Health (U.S.)Hypoxia-Inducible Factor 1medicine.symptomInternational Journal of Radiation Biology
researchProduct

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1993

Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy nec…

DiarrheaMaleLoperamidemedicine.medical_specialtyAbdominal painCancer Researchmedicine.medical_treatmentInjections SubcutaneousOctreotideAdministration OralOctreotideGastroenterologyLoperamidelaw.inventionRandomized controlled triallawChemotherapy-related diarrheaInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)PharmacologyChemotherapybusiness.industryMiddle AgedClinical trialDiarrheaEndocrinologyOncologyChemotherapy-related diarrhea; Loperamide; Octreotide; Cancer Research; Oncology; PharmacologyDefecationFemalemedicine.symptombusinessmedicine.drug
researchProduct

The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.

1989

The therapeutic efficacy of 5-fluorouracil (FUra) and cis-dichlorodiamine-platinum (cis-DDP) in mice bearing transplantable leukemia and solid tumors was evaluated using different sequences of combination of these agents. The optimal sequence was cis-DDP administered 24 h after FUra. The administration of FUra at its maximally tolerated dose (MTD) followed 24 h later by low doses of cis-DDP yielded less toxicity and higher response rate against L1210 and colon 26 than the administration of these two agents in the opposite sequence or concurrently at the MTD. The sequence of administration of these two agents was not therapeutically important when the antitumor activity was evaluated against…

DrugCancer Researchendocrine system diseasesLymphomaRatónmedicine.medical_treatmentmedia_common.quotation_subjectPharmacologyThymidylate synthaseDrug Administration ScheduleMiceAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedAnimalsLeukemia L1210media_commonPharmacologyChemotherapybiologyDose-Response Relationship Drugbusiness.industryThymidylate SynthaseDrug interactionmedicine.diseaseLeukemiaFluorouracilMice Inbred DBAToxicityImmunologyColonic Neoplasmsbiology.proteinFluorouracilCisplatinbusinessmedicine.drugSelective cancer therapeutics
researchProduct

Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.

2018

Many new drugs have appeared in last years in the oncological treatment scenario. Each drug carries an important set of adverse events, not less, cardiovascular adverse events. This aspect is even more important considering the increasing use of combination therapies with two drugs, or three drugs as in some ongoing clinical trials. Besides it represents a growing problem for Cardiologists, that face it in every day clinical practice and that will face it probably more and more in the coming years. This work reviews the mechanism of action of BRAF-inhibitors and MEK-inhibitors used together, the pathophysiological mechanisms that lead to cardiovascular toxicity. Particularly, it focuses on …

DrugCardiovascular toxicityBRAF inhibitorProto-Oncogene Proteins B-rafmedicine.medical_specialtyCombination therapySettore MED/06 - Oncologia Medicamedia_common.quotation_subjectDecreased ejection fraction030204 cardiovascular system & hematologyCardiovascular System03 medical and health sciences0302 clinical medicineCardiovascular toxicityAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)Intensive care medicineAdverse effectBRAF inhibitor; Cardio-oncology; Cardiovascular toxicity; Decreased ejection fraction; Hypertension; MEK inhibitor; Pharmacology; Pharmacology (medical)MelanomaProtein Kinase Inhibitorsmedia_commonPharmacologyMitogen-Activated Protein Kinase KinasesCardiotoxicityMEK inhibitorClinical Trials as Topicbusiness.industryMEK inhibitorCancermedicine.diseaseCardiotoxicityClinical trialCardio-oncology030220 oncology & carcinogenesisHypertensionbusinessPharmacologytherapeutics
researchProduct